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ABSTRACT
Invasive fungal infections are common in severely immunosuppressed patients with cancer and in
recipients of haematopoietic transplants. Response to antifungal therapy alone is often inadequate. Pro-
inflammatory cytokines are critical for promoting innate and adaptive cellular antifungal immune
responses. Recombinant cytokines, including granulocyte–macrophage-colony stimulating factor and
interferon-c, have been studied as adjuvant therapies for severely immunosuppressed cancer patients
with difficult-to-treat invasive mycoses. The limited clinical experience to date shows a possible benefit
of these cytokines, and further controlled clinical trials are needed to validate their routine use in cancer
patients and stem-cell transplant recipients with invasive fungal infections who are likely to have a poor
response to antifungal drug therapy.
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Inhalation of infectious fungal microconidia is a
common source of mould infections, and the
host’s innate immunity is critical during the early
phase of infection. The first line of defence
includes acellular microbiocidal mechanisms,
e.g., activation of complement pathways, cationic
proteins and proteolytic enzymes secreted along
the mucosal lining of the respiratory tract. The
principal cellular reaction during this early non-
antigen-specific innate immune response involves
uptake and elimination of microconidia by alveo-
lar macrophages and neutrophils. The phagocytes
recognise viable infectious microconidia via evo-
lutionarily preserved Toll-like receptors, which
trigger a complex signalling cascade after coming
in contact with the foreign fungal spores [1].
Activation of nuclear factor-jB, and its nuclear
translocation, leads to the induction of various
pro-inflammatory genes that enhance effector
immune cell antimicrobial function. Tumour nec-
rosis factor is another essential mediator in the
early activation of the immune system against
inhaled fungi [2], and promotes selective recruit-
ment of leukocytes at the site of fungal invasion
[3]. Other important neutrophil chemo-attractants
include the ELR (Glu-Leu-Arg tripeptide motif at
the NH2 terminus)-positive subset of CXC chemo-
kines and the corresponding CXCR2 receptors [4].
Chemokine ligand 3 (CCL3) ⁄macrophage inflam-
matory protein-1a and CCL2 ⁄monocyte chemo-
attractant protein-1 are critical in the recruitment
of monocytes and natural killer cells [5]. Other
major chemokines that modulate early innate
immune responses against mould infections in-
clude the macrophage-derived chemokines
(CCL22), which enhance immune response
among monocytes, as well as dendritic cells and
natural killer cells. In contrast, the TH (T-helper)
cell 2-driven thymus and activation-regulated
chemokines (CCL17) suppress immune activation
and impair the innate antifungal pulmonary
defences [6].
Invasive fungal infections are common in
severely immunosuppressed patients with cancer,
and also in recipients of allogeneic haematopoi-
etic transplants [7]. Response to antifungal ther-
apy alone is often inadequate. The adaptive
antigen-specific cellular immune response against
invading fungi is mediated via robust generation
of TH1 cytokines, including interleukin (IL)-12 ⁄ IL-
23, IL-18, IL-2, and interferon (IFN)-c, which
promote the fungicidal activity of the host’s
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mononuclear cells. In contrast, dominance of TH2
cytokines, e.g., IL-4 and IL-10, abrogates the
antifungal protection rendered by the TH1-
dependent antimycotic immune response [8,9].
This abrogation of TH1 antifungal activity can be
restored in experimental animals that have inva-
sive aspergillosis by the administration of TH2
cytokine inhibitors [10].
Interestingly, the host’s cellular and humoral
immune responses appear to be restricted to the
viable and germinating infectious fungal spores
that carry a risk for invasive disease; the mech-
anism by which the host’s adaptive immune
system differentiates between metabolically act-
ive spores and non-disease-causing inactive
spores remains unknown [11].
A number of factors influence the host’s
response to antifungal drug therapy adversely,
including relapsed ⁄ refractory haematological
malignancy, granulocytopenia, myeloablative
anti-neoplastic chemotherapy, high-risk allogene-
ic haematopoietic transplantation, immunosup-
pressive agents used in the treatment of graft vs.
host disease, and high-dose systemic corticoster-
oids [7,12]. Persistent and prolonged chemother-
apy or cancer-related granulocytopenia are
well-established risk-factors for a poor response
to antifungal therapy.
Among the pathogen-associated factors that
may influence the host’s antifungal immune
defences adversely, gliotoxin, the abundant myco-
toxin produced by Aspergillus fumigatus, has been
recognised as being of particular importance.
Gliotoxin suppresses the host’s antifungal innate
and cellular immune responses, and toxin-in-
duced apoptosis of antigen-presenting cells may
be essential for disease-causing fungi to evade the
host’s immune surveillance mechanism [13].
Various strategies to enhance the host’s im-
mune system and to improve treatment of inva-
sive fungal infections in immunosuppressed
cancer patients have been investigated. Granulo-
cyte colony-stimulating factor (G-CSF) and gra-
nulocyte–macrophage colony-stimulating factor
(GM-CSF) have been used successfully for the
treatment of various systemic infections [14]. The
antifungal efficacy of G-CSF probably results
from enhancement of the ability of neutrophils
to kill phagocytosed fungal microconidia via
reactive oxygen species. GM-CSF may promote
effective fungicidal activity via up-regulation of
chitotriosidase, a highly regulated enzyme active
against chitin, which is an integral component of
the fungal cell wall [15]. GM-CSF also reverses
steroid-induced dysfunctions in the handling by
alveolar and tissue macrophages of Aspergillus
microconidia [16,17]. It remains to be seen whe-
ther G-CSF and ⁄ or GM-CSF have a favourable
impact on the neutrophil extracellular (microbio-
cidal) traps [18], which have now been shown to
play an important role in targeted elimination of
non-phagocytosed bacteria.
The addition of G-CSF (5–10 lg ⁄ kg daily)
and ⁄ or GM-CSF (250–500 lg daily) to antifungal
therapy should be considered for selected immu-
nosuppressed cancer patients or stem-cell
transplant recipients with serious and ⁄ or drug-
refractory invasive mycoses. GM-CSF may also be
added to the antifungal regimen for non-neutro-
penic patients, especially those receiving treat-
ment with systemic corticosteroids; however, the
duration of GM-CSF therapy should be limited, as
prolonged therapy may lead to a potentially
serious capillary leak syndrome.
Another cytokine being studied for its enhance-
ment of antifungal therapy is IFN-c, which enhan-
ces the host’s antimicrobial defence by promoting
the intracellular microbiocidal activity of effector
mononuclear cells and polymorphonuclear phag-
ocytes, which are critical in the defence against
filamentous fungi [19,20]. Recombinant human-
ised IFN-c-1b (rhIFN-c-1b) has been given safely to
patients with invasive fungal infection, including
patients with graft vs. host disease following high-
risk allogeneic stem-cell transplantation. Adjuvant
use of this pro-inflammatory cytokine did not
result in serious adverse events, and a measurable
improvement in graft vs. host disease was noted
following rhIFN-c-1b therapy in a number of
patients [19]. The recommended dose of rhIFN-c-
1b for adult patients is 50 lg ⁄m2 of body surface
area, given every other day until resolution of
infection is evident both clinically and radiograph-
ically. In patients with severe, multicentric or
disseminated invasive fungal infection, GM-CSF
may be used initially with rhIFN-c-1b; however,
use of GM-CSF for extended periods may increase
the risk of capillary leak syndrome.
IFN-c is currently regarded as salvage therapy
for patients with refractory invasive fungal infec-
tions that fail to respond to conventional antifun-
gal therapy. However, use of adjuvant immune
modulators, e.g., GM-CSF and rhIFN-c-1b, should
be considered early in the course of invasive
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fungal infections, especially for severely immu-
nosuppressed patients at high risk for failure of
drug therapy. Introducing these immune modu-
lators late in the course of advanced fungal
disease may adversely compromise the potential
therapeutic benefits of exogenous cytokine im-
mune enhancement.
The therapeutic potential of other TH1 cytok-
ines, e.g., IL-2 and IL-12, has also been explored.
However, the use of these recombinant cytokines
is associated with high rates of systemic toxicity,
and they are not recommended for cancer patients
with invasive fungal infections. The therapeutic
value of other TH1 promoters, e.g., IL-18 and
IL-25, requires further investigation.
In patients with severe, refractory neutropenia,
donor granulocyte transfusions have been used
with mixed results. Neutrophils, after migrating
to the site of infection, engulf and kill fungi
through the actions of proteolytic enzymes, anti-
microbial proteins and toxic oxygen radicals.
Similar to neutrophil extracellular traps, which
are composed of granules and nuclear structures
that provide targeted killing of bacteria in the
extracellular milieu, these activated phagocytes
may inundate and kill extracellular tissue-inva-
sive fungi without eliciting a severe inflammatory
response [15]. Various methods to improve the
antimicrobial activity of donor granulocytes have
therefore been explored, including high-dose
granulocytes by transfusion, and adjuvant treat-
ment with recombinant cytokines [20]. The safety
and tolerability of recombinant G-CSF, GM-CSF
and IFN-c therapy in severely neutropenic pa-
tients receiving donor granulocyte transfusions
have been demonstrated [21]. A preliminary
analysis of the antifungal efficacy of this approach
has provided promising results, indicating a need
for large-scale prospective trials.
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